<DOC>
	<DOC>NCT02022020</DOC>
	<brief_summary>This study is being conducted to collect data on the management of gastrointestinal and urogenital bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.</brief_summary>
	<brief_title>Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa</brief_title>
	<detailed_description>Purpose:</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Inclusion criteria: &gt;=18 years of age; Confirmed diagnosis of Atrial Fibrillation (AF); Documentation that the patient had an acute GI and/or GU bleeding event and having taken at least one dose of dabigatran prior to the event. Exclusion criteria: Confirmed diagnosis of valvular AF (VAF); Documentation that the patient was taking dabigatran with other oral anticoagulant; Documentation of the patient receiving thrombolytic therapy prior to the event; Documentation that the patient was enrolled in an investigational clinical trial at the time of the event; Medical record was not available.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>